Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke | Zendy

Zilong Zhu | Zendy; Ying Fu | Zendy; DeCai Tian | Zendy; Na Sun | Zendy; Wei Han | Zendy; Guoqiang Chang | Zendy; Yinhua Dong | Zendy; Xiaolin Xu | Zendy; Qiang Liu | Zendy; DeRen Huang | Zendy; FuDong Shi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke

Author(s) -

Zilong Zhu,

Ying Fu,

DeCai Tian,

Na Sun,

Wei Han,

Guoqiang Chang,

Yinhua Dong,

Xiaolin Xu,

Qiang Liu,

DeRen Huang,

FuDong Shi

Publication year - 2015

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.115.016371

Subject(s) - medicine , fingolimod , stroke (engine) , modified rankin scale , adverse effect , lesion , anesthesia , clinical trial , multiple sclerosis , ischemia , cardiology , ischemic stroke , surgery , immunology , mechanical engineering , engineering

Inflammatory and immune responses triggered by brain ischemia worsen clinical outcomes of stroke and contribute to hemorrhagic transformation, massive edema, and reperfusion injury associated with intravenous alteplase. We assessed whether a combination of the immune-modulator fingolimod and alteplase is safe and effective in attenuating reperfusion injury in patients with acute ischemic stroke treated within the first 4.5 hours of symptom onset.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research